12 hasil untuk "Florence Magrangeas"
Menampilkan 1–12 · 0,35 detik · RSS
-
Artikel Jurnal Teks lengkap
Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles
Multiple myeloma (MM) is a cancer of antibody-making plasma cells. It frequently harbors alterations in DNA and chromosome copy numbers, and can be divided into two major subtypes, hyperdiploid (HMM) and non-hyperdiploid multiple myeloma (NHMM). The two subtypes have different survival prognosis…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study…
-
Artikel Jurnal
Logic programming reveals alteration of key transcription factors in multiple myeloma
Abstract Innovative approaches combining regulatory networks (RN) and genomic data are needed to extract biological information for a better understanding of diseases, such as cancer, by improving the identification of entities and thereby leading to potential new therapeutic avenues. In this…
-
Artikel Jurnal
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
Abstract Splicing changes are common in cancer and are associated with dysregulated splicing factors. Here, we analyzed RNA-seq data from 323 newly diagnosed multiple myeloma (MM) patients and described the alternative splicing (AS) landscape. We observed a large number of splicing pattern changes…
-
Artikel Jurnal
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma
Abstract Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance therapy, in transplant-eligible…
-
Artikel Jurnal
Exploring the impact of dexamethasone on gene regulation in myeloma cells
The study uncovers epigenomic changes associated with dexamethasone response heterogeneity in myeloma cells, revealing rewired promoter–enhancer interactions and DNA loop stabilization. Among glucocorticoids (GCs), dexamethasone (Dex) is widely used in treatment of multiple myelomas. However…
-
Artikel Jurnal
The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability
Abstract Background Cancer evolution depends on epigenetic and genetic diversity. Historically, in multiple myeloma (MM), subclonal diversity and tumor evolution have been investigated mostly from a genetic perspective. Methods Here, we performed an analysis of 42 MM samples from 21 patients by…
-
Artikel Jurnal
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Deletion of the 17p13 chromosomal region [del(17p)] is associated with a poor outcome in multiple myeloma. Most of the studies have targeted the TP53 gene for deletion analyses, although no study showed that this gene is the deletion target. In order to address this issue, we sequenced the TP53…
-
Artikel Jurnal
Genomic patterns of progression in smoldering multiple myeloma
Smoldering MM (SMM) is a premalignant stage of multiple myeloma (MM). Here the authors perform whole genome sequencing of unique paired samples of SMM progressing to MM, and show that the genomic landscape at the SMM stage is very similar to MM, but trajectories of evolution can vary from patient…
-
Artikel Jurnal
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Multiple myeloma evolves continuously. Here the authors chronologically reconstruct driver events in multiple myeloma, noting a limited repertoire of initiating driver events that shape the evolutionary trajectory of the disease.